The use of positron-emitting radionuclides, especially 18 F labeled fluorodeoxy glucose (18 F-FDG), has increased recently due to its role in oncology. This has paved the way to look for other uses for these agents. The use of positron emission tomography (PET) as a noninvasive tool for imaging the heart in coronary artery disease to look for perfusion defects and viability has already been established. This has helped us to know the extent of myocardial blood flow, the metabolic changes occurring in the myocardium, and changes in the cardiac autonomic innervations in various pathological conditions.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
For Further Reading
Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99 m sestamibi SPECT. J Nucl Cardiol. 2006;13:24–33. PubMed: 16464714.PubMedCrossRefGoogle Scholar
Di Carli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation. 2007;115:1464–80.PubMedCrossRefGoogle Scholar
Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, de Kemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging. 2007;34:1765–74.PubMedCrossRefGoogle Scholar